Description: Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors. Noxopharm Limited has a clinical alliance with GenesisCare for the combined therapy of Veyonda and 177Lu-PSMA. The company was incorporated in 2015 and is based in Gordon, Australia.
Home Page: www.noxopharm.com
Tower A, The Zenith
Chatswood,
NSW
2067
Australia
Phone:
61 2 9144 2223
Officers
| Name | Title |
|---|---|
| Dr. Gisela Mautner | CEO, Exec. MD, Chief Medical Officer & Director |
| Mr. Shawn Van Boheemen | Chief Financial Officer |
| Ms. Jeanette Bell Ph.D. | Chief Operating Officer |
| Dr. John Wilkinson B.Sc., Ph.D. | Chief Scientific Officer of Oncology |
| Dr. Olivier Laczka B.S., M.Sc., Ph.D. | Chief Scientific Officer of Inflammation |
| Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP. | Company Sec. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3604 |
| Price-to-Sales TTM: | 7.1059 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |